Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trialKevan C. Herold,Stephen E. Gitelman, M. R. Ehlers,Peter A. Gottlieb,Carla J. Greenbaum,William Hagopian,Karen D. Boyle,Lynette Keyes-Elstein, S. Aggarwal,Deborah Phippard,Peter H. Sayre,James McNamara,Jeffrey A. BluestoneDiabetes Technology & Therapeutics（2014）引用 235|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
